Third quarter 2024 results
Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session.
Upcoming Events
3Dec
2024
7th Annual Evercore ISI HealthCONx Conference
14:30 - 17:30 EDT (Coral Gables, FL)
Broker Conference
4Dec
2024
Berenberg European Conference
08:30 - 16:00 GMT (Surrey, UK)
Broker Conference
4Dec
2024
Citi’s 2024 Global Healthcare Conference
13:00 - 17:00 EDT (Miami, FL)
Broker Conference
Press Releases
November 15, 2024
Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
November 15, 2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
November 14, 2024
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Subscribe to investor email alerts
Sign up to receive email alerts for various types of investor content
Contact Our Investor Relations Team
To join the Sanofi front desk,
Please contact the Global Headquarters in France :
+33 (0)1 53 77 40 00
To contact the Investor Relations team:
46 avenue de la Grande Armée
75017 Paris FRANCE
investor.relations (at) sanofi.com